By Sherri Oslick --
About Court Report: Each week we will report briefly on recently filed biotech and pharma cases.
Abbott Laboratories et al. v. Sandoz Inc.
1:11-cv-00145; filed February 16, 2011 in the District Court of Delaware
• Plaintiffs: Abbott Laboratories; Abbott Respiratory LLC
• Defendant: Sandoz Inc.
Infringement of U.S. Patent Nos. 6,080,428 ("Nicotinic Acid Compositions for Treating Hyperlipidemia and Related Methods Therefor," issued June 27, 2000) and 6,469,035 ("Methods of Pretreating Hyperlipidemic Individuals with a Flush Inhibiting Agent Prior to the Start of Single Daily Dose Nicotinic Acid Therapy to Reduce Flushing Provoked by Nicotinic Acid," issued October 22, 2002) following a Paragraph IV certification as part of Sandoz's filing of an amended ANDA to manufacture a generic version of Abbott's Niaspan® (niacin extended-release tablets, used to treat hypercholesterolemia). View the complaint here.
Leo Pharma A/S v. Perrigo Isrel Pharma Ltd.
1:11-cv-00963; filed February 14, 2011 in the Southern District of New York
Infringement of U.S. Patent No. 6,753,013 ("Pharmaceutical Composition," issued June 22, 2004) following a Paragraph IV certification as part of Perrigo's filing of an ANDA to manufacture a generic version of Leo's Taclones® (betamethasone diproprionate and calcipotriene monohydrate, used to treat psoriasis vulgaris). View the complaint here.
Velcera Inc. et al. v. Merial Ltd.
1:11-cv-00134; filed February 11, 2011 in the District Court of Delaware
• Plaintiffs: Velcera Inc.; Fidopharm Inc.
• Defendant: Merial Ltd.
Declaratory judgment of non-infringement and invalidity of U.S. Patent Nos. 6,096,329 ("Insecticidal Combination to Control Mammal Fleas, in Particular Fleas on Cats and Dogs," issued August 1, 2000), 6,620,943 ("Process for Preparing 4-Trifluoromethylsulfinylpyrazole Derivative," issued September 16, 2003), and 6,881,848 (same title, issued April 19, 2005), all licensed to Merial in the animal health field, based on Plaintiffs' anticipated sale of fipronil-based animal health products. View the complaint here.
Novartis Pharmaceuticals Corp. et al. v. Mylan Pharmaceuticals Inc. et al.
1:11-cv-00015; filed February 11, 2011 in the Northern District of Illinois
• Plaintiffs: Novartis Pharmaceuticals Corp.; Novartis AG
• Defendants: Mylan Pharmaceuticals Inc.; Mylan Inc.
Infringement of U.S. Patent No. 6,242,003 ("Organic Compounds," issued June 5, 2001) following a Paragraph IV certification as part of Mylan's filing of an ANDA to manufacture a generic version of Novartis' Lescol® (fluvastatin sodium, used to treat hypercholesterolemia). View the complaint here.
Comments